Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

This study has been completed.
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer Identifier:
First received: February 12, 2014
Last updated: January 20, 2017
Last verified: January 2017
According to recent guidelines, long-term anticoagulation is recommended for patients with atrial fibrillation (AF) and a risk profile with CHA2DS2-VASc score of 1 or more. Vitamin K antagonists(VAK) and novel oral anticoagulants such as rivaroxaban are current treatment options for AF patients with additional risk factors for stroke. Currently there are only limited information to what extend AF patients prefer one or the other treatment option based on patient relevant characteristics of novel oral anticoagulants vs. VKAs. It is also unknown which of the characteristics influences patient preference most and how this relates to a neutral comparator. Furthermore, an additional unknown factor is also how patient evaluate their current treatment and if this leads to differences among treatment with VKAs and rivaroxaban.

Condition Intervention
Atrial Fibrillation
Drug: Phenprocoumon (Marcumar)
Drug: Rivaroxaban (Xarelto, BAY-59 7939)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • A prescription of patient preferences pattern including 5 attributes for Discrete-Choice-Experiment(DCE)-design in patients with atrial fibrillation [ Time Frame: Within 1-4 weeks after patient enrollement ]
    Attributes and values in relation to the DCE-Choice-Set. The patient will receive a "test card" with the following attributes: bridging of anticoagulation, regular anticoagulation control, limitations to eating behaviour and alcohol consumption, once vs. twice daily intake of medication, neutral comparator for quantification display of preference: distance to therapy practice

  • Patient relevant burden/benefit due to anticoagulation using the ACTS-questionnaire [ Time Frame: At study entry ]

Enrollment: 647
Study Start Date: January 2014
Study Completion Date: October 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
Drug: Phenprocoumon (Marcumar)
common use, no requirements (real life situation)
Group 2
300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
Drug: Rivaroxaban (Xarelto, BAY-59 7939)
common use, no requirements (real life situation)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult AF-patients, within 3 month of anticoagulation (VKA or rivaroxaban) therapy, recruited by GPs

Inclusion Criteria:

A.General Criteria (Group 1and Group2):

  • diagnosed non-valvular AF
  • older than 18 years
  • general capability and willingness to perform a structured patient interview in German
  • no participation in any other clinical or observational study over the last 3 month

Additional criteria for Group1 (VKA-experienced):

  • active VKA-therapy for at least 3 month without significant interruptions
  • in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.

Additional criteria for Group2 (rivaroxaban-experienced patients):

  • active rivaroxaban-therapy for at least 3 month without significant interruptions
  • in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.

Exclusion Criteria:

  • participation in any other clinical or observational study over the last 3 month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02090543

Many Locations, Germany
Sponsors and Collaborators
Janssen Research & Development, LLC
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT02090543     History of Changes
Other Study ID Numbers: 17019
OR-ITW-01-13 ( Other Identifier: Company internal )
Study First Received: February 12, 2014
Last Updated: January 20, 2017

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017